The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trastuzumab (T) and everolimus (E) pharmacokinetics (PK) in HER2 positive (+) primary breast cancer (BC) patients (pts): Unicancer RADHER trial results.
Guillemette Bernadou
No relevant relationships to disclose
Keyvan Rezai
No relevant relationships to disclose
Jean-Louis Merlin
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; Roche; SERVIER
Research Funding - Novartis
Francois Lokiec
No relevant relationships to disclose
Thomas Denis Bachelot
Consultant or Advisory Role - Novartis; Roche
Honoraria - Novartis; Roche
Research Funding - Novartis; Roche
Suzette Delaloge
No relevant relationships to disclose
Veronique Dieras
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Marta Jimenez
Research Funding - Novartis; Roche
David Ternant
No relevant relationships to disclose
Gilles Paintaud
No relevant relationships to disclose